by rss feed | Oct 31, 2026 | Aspen Neuroscience, ER-100 trial, News Feeds, weekly reads
David Sinclair’s firm Life Biosciences recently launched a first-of-its-kind in vivo reprogramming trial called ER-100. I wrote about how the odds were against this trial succeeding but hoped I was wrong to be skeptical. The idea is to use a pulse of OCT4, SOX2,...
